The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of doublet chemotherapy with monotherapy for vulnerable advanced colorectal cancer patients.
 
Mitsuhiro Furuta
No Relationships to Disclose
 
Kentaro Yamazaki
Honoraria - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takeshi Kawakami
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma
 
Hiromichi Shirasu
No Relationships to Disclose
 
Takahiro Tsushima
Honoraria - Bayer; Bayer; Bayer; Bayer; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Nozomu Machida
Honoraria - Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
Research Funding - MSD; MSD; MSD; MSD
 
Satoshi Hamauchi
No Relationships to Disclose
 
Tomoya Yokota
Honoraria - Abbott; Abbott; Abbott; Abbott; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Merck; Merck; Merck; Merck; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD
Research Funding - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Incyte; Incyte; Incyte; Incyte; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer
 
Akiko Todaka
Consulting or Advisory Role - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Akira Fukutomi
Honoraria - Sawai Pharmaceutical Co; Sawai Pharmaceutical Co; Sawai Pharmaceutical Co; Sawai Pharmaceutical Co; Shire; Shire; Shire; Shire; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma; Teijin Pharma; Teijin Pharma; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst)
 
Yusuke Onozawa
Honoraria - Bayer; Bayer; Bayer; Bayer
 
Hirofumi Yasui
No Relationships to Disclose